The review discusses fifty eight peptides in several clinical phases, indicating a sturdy pipeline of peptide therapies concentrating on PPIs. These procedures open new avenues for treatments tailor-made to fight particular breast most cancers subtypes and glioblastoma by honing in on integrins, fibronectins, and matrix metalloproteinases. Th